MRNA vs RGEN

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 13, 2026

MRNA

38.7
AI Score
VS
RGEN Wins

RGEN

54.5
AI Score

Investment Advisor Scores

MRNA

39score
Recommendation
SELL

RGEN

55score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA RGEN Winner
Revenue 1.85B 44.83M MRNA
Net Income -1.96B 3.45M RGEN
Net Margin -106.3% 7.7% RGEN
Operating Income -2.07B 5.98M RGEN
ROE -28.7% 0.6% RGEN
ROA -14.6% 0.5% RGEN
Total Assets 13.47B 743.25M MRNA
Cash 1.20B 173.88M MRNA
Current Ratio 3.62 12.22 RGEN
Free Cash Flow -2.86B 8,000 RGEN

Relative Price Performance (Last 90 Days)

MRNA 1M: +2.2% · 3M: +265.4% RGEN 1M: -6.6% · 3M: -0.2%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (32.0% over 20 days), RSI 53

RSI (14): 52.5 · Price: $231.35

RGEN

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 42

RSI (14): 42.3 · Price: $166.52

Fundamentals Snapshot

Metric MRNA RGEN
Market Cap — —
Forward P/E -53.3 62.8
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.3% 0.1%
Gross Margin -0.4% 0.5%
Operating Margin -0.8% 0.1%
EPS -6.98 -0.21
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, RGEN is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.